Prosecution Insights
Last updated: May 29, 2026

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

8 pending office actions • 5 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Portfolio Summary

8
Total Pending OAs
5
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
4
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 30 days (4)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
5
Medium (62%)
3
Easy (38%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only5 (62%)
§112 only3 (38%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MONTANARI, DAVID A 2 65.1% +49.6%
SHIBUYA, MARK LANCE 1 32.3% +24.9%
SMITH, ADAM MICHAEL 1
GU, QINHUA 1 75.0% +30.4%
NOBLE, MARCIA STEPHENS 1 67.0% +40.2%
WEHBE, ANNE MARIE SABRINA 1 57.6% +42.1%
TINSLEY, BRENDAN THOMAS 1 54.5% +71.1%

Interview Candidates (7)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18010964 GENETICALLY MODIFIED NON-HUMAN ANIMAL EXPRESSING A B2M/FCRN FUSION PROTEIN GU, QINHUA 26d overdue
17790059 GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa/CD47 TINSLEY, BRENDAN THOMAS 3d overdue
18025990 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GLP1R MONTANARI, DAVID A 20d
18277394 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3 GENES SHIBUYA, MARK LANCE 27d
18025302 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CCR8 MONTANARI, DAVID A 29d
17922692 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD94 AND/OR NKG2A NOBLE, MARCIA STEPHENS 30d
17816608 HUMANIZED TRANSGENIC ANIMAL WEHBE, ANNE MARIE SABRINA 56d

Top Art Units

Art UnitApps
1632 3
1634 2
1631 1
1638 1
1633 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18277394 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3 GENES SHIBUYA, MARK LANCE 1631 §103 Non-Final OA 27d Pending Aug 16, 2023
18273631 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC FCRN SMITH, ADAM MICHAEL 1638 §103 Non-Final OA 28d overdue Pending Jul 21, 2023
18025990 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GLP1R MONTANARI, DAVID A 1632 §103 Non-Final OA 20d Pending Mar 13, 2023
18025302 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CCR8 MONTANARI, DAVID A 1632 §103 Non-Final OA 29d Pending Mar 08, 2023
18010964 GENETICALLY MODIFIED NON-HUMAN ANIMAL EXPRESSING A B2M/FCRN FUSION PROTEIN GU, QINHUA 1633 §103 Non-Final OA 26d overdue Pending Dec 16, 2022
17922692 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD94 AND/OR NKG2A NOBLE, MARCIA STEPHENS 1632 §112 Final Rejection 30d Pending Nov 01, 2022
17816608 HUMANIZED TRANSGENIC ANIMAL WEHBE, ANNE MARIE SABRINA 1634 §112 Final Rejection 56d Pending Aug 01, 2022
17790059 GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa/CD47 TINSLEY, BRENDAN THOMAS 1634 §112 Final Rejection 3d overdue Pending Jun 29, 2022

Managing BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month